Two-year follow-up after endobronchial coil treatment in emphysema: results from the REVOLENS study
Authors: Gaëtan Deslée, Sylvie Leroy, Jeanne Marie Perotin, Hervé Mal, Hervé Dutau, Arnaud Bourdin, Jean Michel Vergnon, Christophe Pison, Romain Kessler, Vincent Jounieaux, Mathieu Salaün, Armelle Marceau, Sandra Dury, Jonathan Benzaquen, Margaux Bonnaire, Sylvain Dukic, Coralie Barbe, Charles Hugo Marquette
Journal: European Respiratory Journal (2017)

Severe emphysema is a difficult to treat condition with limited efficacy of currently available treatments. Endobronchial coil treatment (ECT) is a minimally invasive endobronchial treatment which consists of placing shape-memory nitinol coils in emphysematous lobes to enhance lung recoil and reduce lung hyperinflation at rest and during exercise [1, 2]. Randomised studies demonstrated an improvement in exercise capacity, lung function and quality of life, and showed an acceptable safety profile at 1 year [3–6]. However, to our best knowledge, longer term safety and effectiveness results beyond 1 year have not been reported thus far. In severe emphysema, endobronchial coils improve quality of life with an acceptable safety profile at 2 years <http://ow.ly/eVlg30gKrPE> Author's contributions: G. Deslée had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of data analysis. Study concept and design: G. Deslée, C.H. Marquette, C. Barbe; acquisition of data: G. Deslée, S. Leroy, J.M. Perotin, H. Mal, H. Dutau, A. Bourdin, J.M. Vergnon, C. Pison, R. Kessler, V. Jounieaux, M. Salaün, A. Marceau, S. Dury, J. Benzaquen, S. Dukic, M. Bonnaire, C.H. Marquette; analysis and interpretation of data: G. Deslée, C.H. Marquette, C. Barbe; drafting of the manuscript: G. Deslée, C.H. Marquette, S. Leroy, J.M. Perotin; critical revision of the manuscript for important intellectual content: G. Deslée, S. Leroy, J.M. Perotin, H. Mal, H. Dutau, A. Bourdin, J.M. Vergnon, C. Pison, R. Kessler, V. Jounieaux, M. Salaün, A. Marceau, S. Dury, J. Benzaquen, M. Bonnaire, S. Dukic, C. Barbe, C.H. Marquette; statistical analysis: C. Barbe; study supervision: G. Deslée. Members of the REVOLENS Study Group: The members of the REVOLENS Study Group include all authors and Hervé Vallerand, François Lebargy, Claire Launois (Hôpital Universitaire de Reims), Johanna Pradelli, Matthieu Buscot, Celine Sanfiorenzo, Sylvie Korzeniewski, Andrea Mazzetta, Jennifer Griffonnet, Ariane Guillemart, Demosthenes Makris (Hôpital Universitaire de Nice), Marie Christine Dombret, Frédérique Servin, Marie Pierre Debray (Hôpital Universitaire Bichat, Paris), Sophie Laroumagne, Fabienne Bregeon, Carine Gomez, Philippe Astoul (Hôpital Universitaire de Marseille), Nathalie Lesavre (Centre d'Investigation Clinique 1409, AP-HM, Marseille), Jean Pierre Mallet, Anne Sophie Gamez, Philippe Tarodo, Christophe Brousse, Clément Broissin (Hôpital Universitaire de Montpellier), Yoann Thibout, Fabrice Di Palma, Frédéric Costes (Hôpital Universitaire de Saint Etienne), Amandine Briault, François Arbib, Emilie Reymond (Hôpital Universitaire de Grenoble), Michele Porzio, Benjamin Renaud-Picard (Hôpital Universitaire de Strasbourg), Bénédicte Toublanc, Géraldine François (Hôpital Universitaire d'Amiens), Luc Thiberville, Antoine Cuvelier, Samy Lachkar (Hôpital Universitaire de Rouen), Delphine Gras (Monitoring team, Hôpital Universitaire de Reims), Philippe Benoit (Pharmacie, Hôpital Universitaire de Reims), Annick Leclainche, Damien Jolly (Pôle recherche et innovation, Hôpital Universitaire de Reims). Data and Safety Management Board: François Fourrier, Eric Hachulla, Nicolas Roche, Daniel Dusser. The collaborators did not receive any compensation for their contribution.